Novakand Pharma AB (FRA:3EE0) OCF Margin %: 0.00% (As of Dec. 2025)


What is Novakand Pharma AB OCF Margin %?

Novakand Pharma AB FRA:3EE0 OCF Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Novakand Pharma AB ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Novakand Pharma AB's Cash Flow from Operations for the three months ended in Dec. 2025 was €-0.57 Mil. Novakand Pharma AB's Revenue for the three months ended in Dec. 2025 was €0.00 Mil. Therefore, Novakand Pharma AB's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Novakand Pharma AB's current OCF Yield % is -560.41%.

The historical rank and industry rank for Novakand Pharma AB's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Novakand Pharma AB was -724.01%. The lowest was -47381.42%. And the median was -6316.33%.

FRA:3EE0's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Novakand Pharma AB OCF Margin % Related Terms

Novakand Pharma AB OCF Margin % Historical Data

* Premium members only.

The historical data trend for Novakand Pharma AB's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novakand Pharma AB OCF Margin % Chart

Novakand Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,587.95 -6,361.76 0.00 0.00 0.00

Novakand Pharma AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Novakand Pharma AB OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Novakand Pharma AB's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-2.783/0
= %

Novakand Pharma AB's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.569/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Novakand Pharma AB (FRA:3EE0) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Novakand Pharma AB and its competitors. According to the industry distribution chart, Novakand Pharma AB ranks #999999 out of 959 companies in the Biotechnology industry.
Is Novakand Pharma AB's OCF Margin % too high?
Novakand Pharma AB's current OCF Margin % is 0.00%. Based on the distribution chart, Novakand Pharma AB ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Novakand Pharma AB's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Novakand Pharma AB ranks #999999 out of 959 companies for OCF Margin %. This places Novakand Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Novakand Pharma AB and its competitors. Novakand Pharma AB's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novakand Pharma AB stock overvalued right now?
Novakand Pharma AB (FRA:3EE0) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Novakand Pharma AB (FRA:3EE0), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novakand Pharma AB Business Description

Address Nanna Svarts vag 4, Solna, SWE, 171 65
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.